Table 2.
Baseline characteristics of pT1−3N1M0 and pT4NanyM0 groups before and after matching, SEER 2004-2015.
| Characteristic | Before matching | After matching* | ||||
|---|---|---|---|---|---|---|
| Stage III-N1 | Stage IV-M0 | P† | Stage III-N1 | Stage IV-M0 | P† | |
| pT1−3N1M0 | pT4NanyM0 | pT1−3N1M0 | pT4NanyM0 | |||
| (N = 446, %) | (N = 105, %) | (N = 105, %) | (N = 105, %) | |||
| Age, mean (95%CI), y | 60.2 (59.1–61.3) | 59.7 (57.8–61.6) | 0.71 | 61.5 (59.3–63.6) | 59.7 (57.8–61.6) | 0.23 |
| Sex | 0.034 | 0.39 | ||||
| Male | 323 (72.4) | 65 (61.9) | 71 (67.6) | 65 (61.9) | ||
| Female | 123 (27.6) | 40 (38.1) | 34 (32.4) | 40 (38.1) | ||
| Race | 0.44 | 0.56 | ||||
| White | 359 (80.5) | 88 (83.8) | 91 (86.7) | 88 (83.9) | ||
| Non-white | 87 (19.5) | 17 (16.2) | 14 (13.3) | 17 (16.2) | ||
| Grade | 0.25 | 0.98 | ||||
| Well/moderately | 81 (18.2) | 13 (12.4) | 13 (12.4) | 13 (12.4) | ||
| Poor | 224 (50.2) | 53 (50.5) | 53 (50.5) | 53 (50.5) | ||
| Undifferentiated | 102 (22.9) | 32 (30.5) | 32 (30.5) | 32 (30.5) | ||
| Unknown | 39 (8.7) | 7 (6.7) | 7 (6.7) | 7 (6.7) | ||
| Tumor site | 0.74 | 0.58 | ||||
| Left | 247 (55.4) | 60 (57.1) | 64 (61.0) | 60 (57.1) | ||
| Right | 199 (44.6) | 45 (42.9) | 41 (39.0) | 45 (42.9) | ||
| Histology | 0.002 | 0.99 | ||||
| Clear cell | 286 (64.1) | 84 (80.0) | 84 (80.0) | 84 (80.0) | ||
| Chrompohobe | 21 (4.7) | 6 (5.7) | 6 (5.7) | 6 (5.7) | ||
| Papillary | 139 (31.2) | 15 (14.3) | 15 (14.3) | 15 (14.3) | ||
| T stage | NA | NA | ||||
| T1 | 61 (13.6) | 0 (0.0) | 16 (15.2) | 0 (0.0) | ||
| T2 | 81 (18.2) | 0 (0.0) | 21 (20.0) | 0 (0.0) | ||
| T3a | 216 (48.4) | 0 (0.0) | 48 (45.7) | 0 (0.0) | ||
| T3b | 71 (15.9) | 0 (0.0) | 16 (15.2) | 0 (0.0) | ||
| T3c | 10 (2.2) | 0 (0.0) | 2 (1.9) | 0 (0.0) | ||
| T3NOS | 7 (1.6) | 0 (0.0) | 2 (1.9) | 0 (0.0) | ||
| T4 | 0 (0.0) | 105 (100.0) | 0 (0.0) | 105 (100.0) | ||
| N stage | NA | NA | ||||
| N0 | 0 (0.0) | 88 (83.8) | 0 (0.0) | 88 (83.8) | ||
| N1 | 446 (100.0) | 17 (16.2) | 105 (100.0) | 17 (16.2) | ||
| Invasion beyond capsule‡ | NA | NA | ||||
| No | 148 (50.0) | 12 (17.1) | 30 (45.5) | 12 (17.1) | ||
| Yes | 122 (41.2) | 56 (80.0) | 30 (45.5) | 56 (80.0) | ||
| Unknown | 26 (8.8) | 2 (1.9) | 6 (9.1) | 2 (2.9) | ||
| Fuhrman nuclear grade‡ | NA | NA | ||||
| Grade 1/2 | 37 (12.5) | 10 (14.3) | 8 (12.1) | 10 (14.3) | ||
| Grade 3 | 143 (48.3) | 33 (47.1) | 25 (37.9) | 33 (47.1) | ||
| Grade 4 | 84 (28.4) | 25 (35.7) | 29 (43.9) | 25 (35.7) | ||
| Unknown | 32 (10.8) | 2 (2.9) | 4 (6.1) | 2 (2.9) | ||
| Sarcomatoid features‡ | NA | NA | ||||
| Absence | 248 (83.8) | 55 (78.6) | 56 (84.8) | 55 (78.6) | ||
| Presence | 37 (12.5 | 14 (20.0) | 7 (10.6) | 14 (20.0) | ||
| Unknown | 11 (3.7) | 1 (1.4) | 3 (4.5) | 1 (1.4) | ||
| LNs examined, mean (95%CI) | 9 (7–11) | 8 (6–10) | 0.70 | 11 (6–16) | 8 (6–10) | 0.29 |
| LNs positive, mean (95%CI) | 6 (4–8) | 1 (0–2) | 9 (4–14) | 0 (0–0) | ||
LN, lymph node; CI, Confidence interval; NA, Not applicable.
*
Adjusted for group, age, grade, and histology.
†
Derived from χ2-test for categorical variables, general linear models for continuous variables.
‡
Invasion beyond capsule, fuhrman nuclear grade, and sarcomatoid features were only applicable for 2010+ cases, and not enter into the χ2-test, thus the P-value was not applicable.